Fierce Pharma

JULY 11, 2024

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.

Pharma 339

Pharma Competition 339

Clarivate

JULY 11, 2024

“AI Everywhere All at Once.” This year’s theme from Outsell, Inc. perfectly captures the expansion of artificial intelligence across all facets of our lives. In academia, this rapid advancement raises more questions than answers. How do we ensure ethical AI use? How can we advance research and drive research integrity? How do we use AI to advance student learning skills?

Ethics 122

Ethics Education Marketing Government 122

Fierce Pharma

JULY 11, 2024

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | On top of Eisai and Biogen's Leqembi, Kisunla’s approval likely marks the “end of the beginning in treating this disease,” Andrew Lechleiter, VP of U.S.

Marketing 308

Marketing FDA 308

pharmaphorum

JULY 11, 2024

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.

Prescription 119

Prescription Medicine Pharma Patients 119

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JULY 11, 2024

Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear. | Equipped with two approved meds from Acorda Therapeutics, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.

258

258

MedCity News

JULY 11, 2024

By understanding that AUD is a diagnosable and treatable medical condition with individualized impact, we can tailor treatments to meet patients’ specific needs. Effective treatment for AUD is multifaceted, involving medical, psychological, and social support. The post Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD) appeared first on MedCity News.

Medical 115

Medical Patients FDA Biopharma 115

MedCity News

JULY 11, 2024

Amedisys and UnitedHealth Group plan to divest care centers to an affiliate of VitalCaring Group. Several experts said this will likely clear the way for the companies’ merger. The post Will A Divestiture Save the UnitedHealth Group-Amedisys Deal? appeared first on MedCity News.

115

115

Fierce Pharma

JULY 11, 2024

The dog days of summer might be in full swing, but for flu vaccine makers, its a busy time prepping for this fall's influenza season. | The companies started distributing shipments of their respective vaccine options ahead of the fall flu season as the CDC recommends vaccination before the virus spreads.

Distribution 234

Distribution 234

European Pharmaceutical Review

JULY 11, 2024

Dr Roopal Thakkar has been appointed as Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie. He is the company ’s current Senior Vice President, Chief Medical Officer, Global Therapeutics. “As AbbVie’s Chief Scientific Officer, Dr Thakkar will continue to build momentum across discovery and all stages of development to fully realise the potential of our diverse pipeline.

Medicine 105

Medicine Medical Leads Training 105

Fierce Pharma

JULY 11, 2024

In surging to the top spot in the market cap rankings in Europe, Novo Nordisk has been on an extended winning streak. | The FDA has slowed the roll for Novo Nordisk, rejecting its once-a-week insulin icodec for patients with Type 1 and Type 2 diabetes. In a complete response letter, the U.S. regulator made "requests related to the manufacturing process and the type 1 diabetes indication," which the company said it does not expect to remedy by the end of this year.

Manufacturing 233

Manufacturing FDA Marketing Patients 233

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

pharmaphorum

JULY 11, 2024

The FTC is said to be gearing up to file lawsuits against the top three pharmacy benefit managers in the wake of its damning report on the sector.

Management 115

Management 115

Fierce Pharma

JULY 11, 2024

After a rocky road to approval and two amendments to the original pact, Akebia Therapeutics and CSL Vifor have terminated their collaboration around the oral chronic kidney disease (CKD) anemia dru | As it ends a licensing agreement with CSL Vifor, Akebia has priced its chronic kidney disease anemia drug Vafseo by incorporating an uncertain future label expansion that it plans to discuss with the FDA later this year.

FDA 226

FDA 226

pharmaphorum

JULY 11, 2024

Tune in to Caroline Redecker and Jason Casarella as they discuss clinical trial trends and the rise of site networks in this insightful podcast episode brought to you by Advanced Clinical.

Networking 98

Networking 98

Fierce Pharma

JULY 11, 2024

In this episode of "The Top Line", sponsored by the Parenteral Drug Association (PDA), we do a deep dive into the highly anticipated PDA/FDA Joint Regulatory Conference, set to take place from Sept | We sat down with industry expert Janeen Skutnik-Wilkinson, the PDA/FDA Joint Regulatory Conference 2024 Co-Chair to give us an exclusive behind-the-scenes look at this must-attend CGMP event, set to take place from September 9-11 in Washington D.C.

FDA 130

FDA 130

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

JULY 11, 2024

FDA rejects Novo Nordisk’s once-weekly basal insulin for people with diabetes, which would reduce the number of injections needed

FDA 107

FDA 107

MedCity News

JULY 11, 2024

Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama. The post Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug appeared first on MedCity News.

Biopharma 93

Biopharma Pharma 93

PharmaTimes

JULY 11, 2024

Macmillan Cancer Support estimates that cancer affects over three million people in the UK

Government 105

Government 105

pharmaphorum

JULY 11, 2024

Ipsen places another bet on an antibody-drug conjugate for cancer, pledging up to $1bn for a preclinical candidate from Foreseen Bio

91

91

Advertisement

MedCity News

JULY 11, 2024

Solving three major challenges in the development of new oncology drugs The post The Opportunity for Digital Innovation in Oncology Drug Development appeared first on MedCity News.

FDA 76

FDA Patients Pharma 76

pharmaphorum

JULY 11, 2024

Change of R&D chiefs at AbbVie, as Thomas Hudson steps down as CSO and is replaced by Roopal Thakkar.

96

96

MedCity News

JULY 11, 2024

The number of hospital M&A deals may have fallen from Q1 to Q2 of this year, but that doesn’t mean that the hospital M&A space is lacking vitality, according to a new Kaufman Hall report. Rather, it means that the hospital M&A is shifting its emphasis from scale to strategy. The post Hospital M&A Activity Remained Strong In Q2, Kaufman Hall Says appeared first on MedCity News.

63

63

PharmaTimes

JULY 11, 2024

The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care

Networking 91

Networking 91

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Commerce

JULY 11, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

Scott’s Directories

JULY 11, 2024

In Manitoba, the healthcare sector thrives, offering vast market opportunities. For businesses targeting this industry, access to a comprehensive physician directory in Manitoba is invaluable. Whether you’re a pharmaceutical company, a medical equipment supplier, or a healthcare recruiter, having a detailed Manitoba medical directory can significantly enhance your outreach efforts.

Doctors 52

Doctors Marketing Physicians Medical 52

Clarify Health

JULY 11, 2024

As health plans seek innovative strategies to enhance their service offerings and improve financial performance, the integration of telemedicine into their networks emerges as a pivotal solution. By leveraging data analytics to optimize and expand telemedicine capabilities, payers can effectively address the critical challenge of extending quality healthcare to underserved areas while managing costs.

Networking 52

Networking Healthcare Healthcare Patients 52

Contrarian Sales Techniques

JULY 11, 2024

Meet Wei Wei isn't your typical high-flying pharma rep. Forget fancy suits and briefcases overflowing with brochures for the latest wonder drug. This 50-year-old rolls up his sleeves and hits the dusty roads in his trusty Perodua Alza, a familiar sight in the rural areas he frequents. The truth is, Wei used to be that kind of rep. All charm and spiel, pushing expensive branded meds on busy doctors.

Doctors 52

Doctors Medical Sales Pharma Rep 52

Advertisement

Distribution

Pharmaceutical Commerce

JULY 11, 2024

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

Patients 52

Patients Pharma 52

Contrarian Sales Techniques

JULY 11, 2024

Desperation Drive Ugh, another rejection email. Same old, same old. "We're happy with our current supplier," it read. Yeah, right. Like I haven't heard that a million times before. Slamming my laptop shut, I buried my face in my hands. This wasn't just a slump. My sales career was in the toilet. Rent was due, my ramen noodle supply was dwindling, and the only spark in my love life came from the static on my perpetually on TV.

Doctors 52

Doctors Sales Patients Medical 52

PharmExec

JULY 11, 2024

According to the Complete Response Letter, the FDA has requested additional information on the manufacturing process and the type 1 diabetes indication for insulin icodec before completing its review.

FDA 52

FDA Manufacturing 52

Pharmacy Times

JULY 11, 2024

In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.

Management 64

Management Pharmaceutical 64

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales